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Abstract
Background: Diagnosis of breast cancer during pregnancy was formerly considered an indication
for abortion. The pendulum has since swung to the other extreme, with most reviews now
rejecting termination while endorsing immediate anthracycline-based therapy for any pregnant
patient beyond the first trimester. To assess the evidence for this radical  change in thinking, a
review of relevant studies in the fields of breast cancer chemotherapy, pregnancy, and drug safety
was conducted.
Discussion: Accumulating evidence for the short-term safety of anthracycline-based
chemotherapy during late-trimester pregnancy represents a clear advance over the traditional
norm of therapeutic abortion. Nonetheless, the emerging orthodoxy favoring routine
chemotherapy during gestation should continue to be questioned on several grounds: (1) the
assumed difference in maternal survival accruing from chemotherapy administered earlier – i.e.,
during pregnancy, rather than after delivery – has not been quantified; (2) the added survival benefit
of adjuvant cytotoxic therapy prescribed within the hormone-rich milieu of pregnancy remains
presumptive, particularly for ER-positive disease; (3) the maternal survival benefit associated with
modified adjuvant regimens (e.g., weekly schedules, omission of taxanes, etc.) has not been proven
equivalent to standard (e.g., post-delivery) regimens; and (4) the long-term transplacental and
transgenerational hazards of late-trimester chemotherapy are unknown.
Summary: Although an incrementally increased risk of cancer-specific mortality is impossible to
exclude, mothers who place a high priority on the lifelong well-being of their progeny may be
informed that deferring optimal chemotherapy until after delivery is still an option to consider,
especially in ER-positive, node-negative and/or last-trimester disease.
Background
Immediate chemotherapy may be clearly indicated for
pregnant breast cancer patients with unresectable primary
tumors or metastatic presentations, whereas operable
tumors raise a more complex conflict of interest: the
mother is threatened directly by cancer recurrence and
hence, indirectly, by any treatment compromise made on
behalf of the fetus. Decisions made in this context tend to
be less drastic for the mother than for the fetus, given that
the latter has more life-years to lose, and faces health haz-
ards that are wholly avoidable. This risk imbalance is
worsened by the weaker advocacy position of the fetus,
who tends not to be considered the primary 'client' in
such oncologic scenarios.
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Recent studies have emphasized the safety of adjuvant
anthracycline-based drug therapy during the second and
third trimesters [1-5]. The post-resection dilemma in late-
trimester cases can thus be reduced to three choices: termi-
nation of pregnancy followed by state-of-the-art adjuvant
treatment; continuation of pregnancy with immediate
administration of modified chemotherapy regimens that
typically lack antimetabolites [6,7], taxanes [2] and trastu-
zumab [8] due to safety uncertainties; or continuation of
pregnancy with optimal  chemotherapy given after deliv-
ery (Figure 1). Exclusive prioritization of decision-making
towards the physical health of the mother favors termina-
tion followed by standard treatment, whereas prioritiza-
tion towards the physical health of the fetus favors
deferral of all nonsurgical treatments until after delivery.
Many oncologists now see the option of second- and
third-trimester cytotoxic therapy (hereinafter termed ges-
tational chemotherapy) as a happy medium between
these conservative and pro-active management positions,
not least because of carefully-worded endorsements of
anthracycline-based therapies as capable of being given
with "minimal complications of labor and delivery" [1] or
"minimal risk to the fetus" [2].
Therapeutic delay
A central belief underlying the new enthusiasm for gesta-
tional chemotherapy is that delay of adjuvant cancer treat-
ment is substantially deleterious to maternal outcomes.
Taken to extremes, this assumption must be valid: if adju-
vant treatment is delayed until metastases appear, the
opportunity for cure has been lost. Such logic likewise
supports the utility of therapeutic abortion which,
uniquely, permits full deployment of all adjuvant modal-
ities according to standard time-schedules. Relevant to
this, however, no survival benefit attributable to therapeu-
tic abortion has yet been proven [5],  despite the fact that
this option enables the most standard adjuvant therapy
scheduling.
At present, there are no controlled data defining the extent
to which a less extreme delay in the initiation of adjuvant
therapy impairs overall survival outcomes. Retrospective
studies have indicated that adjuvant chemotherapy delays
of up to three months have no discernible effect on prog-
nosis [9,10]; only in very advanced disease has delay in
initiating adjuvant chemotherapy been associated with
any impairment of disease-free survival [11], though
other groups have failed to demonstrate impaired overall
survival in any patient subset [12]. Using a model that
quantifies risk increments in patients deferring breast can-
cer chemotherapy until after delivery, Nettleton et al esti-
mated a modest 1.5–4.0% increased risk of transforming
from axillary node-negative to -positive [13] in late-tri-
mester patients, assuming a typical 10–12 week delay
[14]. A large retrospective review of premenopausal
patients indicated that only patients with ER-absent
tumors are likely to benefit from early initiation of adju-
vant chemotherapy [15].
Therapeutic benefit
While it is reasonable to believe that gestational chemo-
therapy confers survival benefits similar to those apparent
in overviews of nonpregnant patients receiving conven-
tional chemotherapy [16], such overviews only calculate
average effects, and should not be extrapolated to patient
subsets affected by qualitative interactions [17]. Preg-
nancy represents exactly such an interaction: dramatic
changes of mammary gland gene expression are induced
by the presence of the fetus [18], reflecting corresponding
changes in the tumor microenvironment. Breast cancer
survival outcomes vary inversely with diagnostic proxim-
ity to earlier pregnancy [19,20], raising the possibility of
biological resistance to adjuvant treatments. Since the
benefit of chemotherapy tends to be lower for hormone-
driven tumors in both the adjuvant [21] and neoadjuvant
settings [22-24], and appears similar to that of ovarian
suppression in premenopausal women with hormone-
dependent disease [25,26], the question arises: for preg-
nant patients whose tumors express some hormone recep-
Schematic representation of patient choices for adjuvant therapies in res ctable primary breast cancer diagnosed in  second or third trimeste sFigure 1
Schematic representation of patient choices for adjuvant 
therapies in resectable primary breast cancer diagnosed in 
the second or third trimesters. A, Immediate termination; B, 
Chemotherapy during pregnancy; C, Chemotherapy after 
pregnancy; D, No chemotherapy.Page 2 of 5
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hormone-rich pregnancy environment necessarily be
more effective than similar chemotherapy given after
delivery; or could the opposite be the case?
A further worry raised by the vogue for gestational chem-
otherapy is the possibility that suboptimal regimens may
be delivered, albeit with good intentions; in the worst of
all possible worlds, such regimens could imperil the fetus
without benefiting the mother. For example, Peccatori et
al treated pregnant patients using weekly epirubicin 30–
50 mg/m2 with the aim of maximizing therapeutic effect
while minimizing fetal drug exposure [27]. However, the
adjuvant efficacy of such customized regimens – whether
in pregnant or non-pregnant patients – is simply not
known, though it is accepted that "low-dose" chemother-
apy regimens are less effective. Other modifications of
standard regimens – e.g., exclusion of antimetabolites
and/or taxanes, lower dose-intensity and/or dose-density,
or withholding of the humanized antibody trastuzumab –
are popular in this setting, raising the question: is the
administration of such 'modified' regimens during preg-
nancy aimed at treating the patient or the doctor? If a preg-
nant breast cancer patient does not receive chemotherapy
of similar efficacy to that received by nonpregnant
patients, should it be assumed that this deficiency will be
rectified in the post-partum period – or would it be better
to defer the entire treatment regimen until after delivery,
at which time a more concentrated and intensive
approach could plausibly improve survival benefits?
Therapeutic safety
The usual endpoints that have been used to determine the
fetal 'safety' of late-trimester chemotherapy include con-
genital malformations, developmental milestones and
pediatric tumor rate. Indeed, the literature is replete with
series [28,29] and case reports [30-32] of 'safe' treatment
anecdotes where no obvious fetal malformation was doc-
umented following gestational chemotherapy. Yet as reas-
suring as these negative reports sound, they may not
reflect the actual toxicity of late-trimester chemotherapy.
Intrauterine growth retardation, miscarriages, stillbirths,
pre-eclampsia and prematurity are increased in pregnan-
cies involving cytotoxic treatment [33], yet are not ranked
as malformations or teratogenicity. As listed in Table 1,
more subtle long-term deficits in transplacentally-exposed
progeny – such as reduced fertility, fine cognitive deficien-
cies, more frequent adult solid tumors, diminished lon-
gevity, or transgenerational carcinogenesis – may become
apparent in "chemo babies" only after long-term surveil-
lance [34].
A further safety-related concern is that a future pregnancy
is possible, but not guaranteed. The summative risks of
chemotherapy-induced infertility (say, 20%), early meta-
static relapse (say, 20%) or marital problems (say, 10%)
might be expected to reduce the certainty of having
another baby, keeping in mind that the duration of any
adjuvant hormonal therapy is likely to be five years or
longer. Although it is difficult to quantify the relative net
fertility outcomes of early vs. late chemotherapy in this
context, it is certainly arguable that the fetus of a pregnant
breast cancer patient may be, if anything, more precious
to the mother than the average pregnancy, given the
uncertain prognoses for both maternal survival and fecun-
dity.
Moreover, patients may believe that the most painful
choice – in this case, abortion, which is chosen in up to
50% of cases in many international series [35] – must be
the best [36]. Clinicians aware of the anxieties facing the
patient may feel obliged to offer active intervention ("at
least we're doing something"), unintentionally biasing
informed consent [37]. Patient acceptance of gestational
chemotherapy may likewise have more to do with cultural
norms of cooperation and punishment [38] than with
logical consideration of all options. These concerns sup-
port reservations expressed by Barthelmes et al [39], Pau-
tier et al [40] and Mathieu et al [41] about the trend
towards routine immediate adjuvant chemotherapy for
late-trimester breast cancer patients.
Summary
Oncologists may be less familiar than obstetricians with
the ethical complexities confronting pregnant patients.
Management of cancer in pregnancy is complicated by the
tendencies of clinicians to equate (maternal) risk with
(maternal plus fetal) benefit, to assume that immediacy of
action is always best, to hold the interests of the 'client'
(mother) above those of any third party (fetus), and to
imply that lack of proven danger equals safety. Basing
standard recommendations on such convictions is tempt-
Table 1: Expected vs. non-expected positive endpoints for 
gestational exposure to cytotoxic drugs.
Expected effects of transplacental mutagens in late-
trimester pregnancies
Expected to be normal Expected to be abnormal
Congenital malformation rate Abortion rate
Postnatal apgar indices Prematurity, stillbirth
Neurologic milestones Birth weight
Infant sexual/genital development Adult fertility




Short-term cardiovascular function Long-term cardiovascular 
function
Learning ability LongevityPage 3 of 5
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biology, measured therapeutic benefits, and longer-term
toxicity data is needed before any such standard can be
scientifically endorsed [42]. In the meantime, the debate
will continue as to whether chemotherapy should be pre-
sumed 'innocent until proven guilty' or 'guilty until
proven innocent': although the Hippocratic ethical
maxim "First, do no harm" favors the latter from the view-
point of the fetus, an assumption of gestational chemo-
therapy efficacy will favor the former from the viewpoint
of the mother.
The inconvenient truth remains that gestational chemo-
therapy has not yet been proven to have net benefits
(long-term maternal survival increments minus long-term
fetal toxicities) exceeding those of delayed chemotherapy.
Equally, however, there remains insufficient data to claim
that delayed chemotherapy should be standard, and the
issue is likely to remain unresolved. Nonetheless, deferral
of chemotherapy to the post-partum period remains a
valid and defensible option for oncologists to invite
selected late-trimester breast cancer patients – e.g., those
with hormone receptor-positive disease, node-negative
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